AsianScientist (Dec. 12, 2024) –Liquid biopsy has been gaining traction as a robust instrument to detect and diagnose most cancers. A minimally invasive and simply repeatable process, it’s used to display for biomarkers in biofluid samples, which embrace numerous types of freely circulating DNA fragments generally known as cell-free DNA (cfDNA). Along with next-generation sequencing (NGS), cfDNA-based liquid biopsy marks a promising alternative for earlier detection and creating extra customized therapies for most cancers.
Sequencing cfDNA, nevertheless, is difficult as cfDNA is definitely degraded and its focus in fluid samples is usually low. This results in low library yield and low imply goal protection, affecting the detection of variants of low allele frequencies and the identification of low-frequency biomarkers. To deal with these points, main biotechnology and genomics firm Twist Bioscience has developed the Twist cfDNA Library Preparation Equipment that permits high-yield cfDNA libraries for NGS.
“The most recent in our NGS portfolio, the Twist cfDNA Library Preparation Equipment overcomes the widespread problem of liquid biopsy purposes and most cancers analysis workflows the place there’s low pattern enter however a necessity for prime efficiency,” mentioned Emily M. Leproust, PhD, CEO and co-founder of Twist Bioscience.
In comparison with different cfDNA library preparation kits obtainable available in the market, Twist Bioscience’s providing stories a two-times enchancment in conversion charge, which interprets to greater yields, higher imply goal protection and extra delicate and correct detection of variants of low allele frequencies, together with uncommon variants. A strong efficiency is predicted even with low cfDNA pattern inputs of 1 to twenty ng/ml.
“We’ve got developed a brand new ligase, together with an optimized protocol and buffer formulation, that enables for elevated conversion effectivity and quick response occasions even with low enter quantities. Greater conversion generates greater yields which result in greater sensitivity,” shared Dr Leproust, who pressured the numerous enhancements in total efficiency with the brand new cfDNA Library Preparation Equipment.
A high-yield library is essential to enabling correct detection of cfDNA-based biomarkers in NGS. As an example, circulating tumor DNA (ctDNA)—a type of cfDNA derived from tumors and cancerous cells—accommodates worthwhile info contributing to most cancers prognosis and prognosis, however its extremely fragmented nature makes it arduous to detect. With its excessive conversion charge, the Twist cfDNA Library Preparation Equipment helps develop extra delicate ctDNA assays for oncology analysis.
Since its launch in February 2024, the Twist cfDNA Library Preparation Equipment has generated a buzz amongst clinicians and researchers. One laboratory in Asia-Pacific utilizing the equipment to detect low-frequency variants of somatic mutations has noticed a 30 % enhance in protection regardless of having low pattern inputs. This end result was additionally achieved with fewer PCR cycles, lowering each turnaround time and bias.
The answer is designed for workflow effectivity, producing sequence-ready libraries inside two hours whereas minimizing error charges and sequencing reruns. It is available in two configurations: the cfDNA Library Preparation Equipment for complete genome sequencing and the Twist cfDNA Library Preparation and Hybridization Combine Equipment for goal enrichment.
Complementing the equipment is the Twist cfDNA Pan-Most cancers Reference Commonplace v2, a set of high-quality standardized controls that can be utilized to ascertain the analytical restrict of detection (LoD) and restrict of clean (LoB) for particular most cancers variants. It additionally serves as a management to trace the standard of an NGS assay workflow and assess the constancy of the assay course of throughout analysis. The reference normal boasts over 400 variant websites spanning 84 genes, and might be built-in into Twist Bioscience’s vary of goal enrichment options effortlessly.
The corporate’s newest cfDNA-based choices elevate the potential of liquid biopsy in numerous purposes, such because the early detection of most cancers, tumor profiling and the monitoring of molecular adjustments within the illness. Additionally they mark the corporate’s centered dedication to broadening and bettering its NGS portfolio because it stands on the forefront of analysis for precision oncology and customized remedy.
“The usage of cfDNA in an NGS workflow has change into a key instrument in analysis and scientific purposes. Twist Bioscience leverages its core expertise to develop novel options and optimize present ones to push the boundaries of NGS and form the way forward for most cancers analysis,” concluded Dr Leproust.
Contact Twist Bioscience right here to find progressive options for cfDNA-based liquid biopsy.
—
Supply: Twist Bioscience, Shutterstock
Disclaimer: This text doesn’t essentially replicate the views of AsianScientist or its workers.
